Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $25.50 Average PT from Brokerages

Key Points

• Crescent Biopharma, Inc. (NASDAQ:CBIO) has received an average rating of "Buy" from five analysts, with a target price averaging $25.50.
• The company recently reported a quarterly loss of ($4.93) earnings per share, missing the consensus estimate by ($2.24).
• Despite a current trading price of $13.08, the stock has experienced significant volatility, showing a 12-month low of $10.83 and a high of $63.00.

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the five brokerages that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $25.50.

CBIO has been the subject of a number of recent analyst reports. Wedbush initiated coverage on shares of Crescent Biopharma in a research report on Monday, July 14th. They issued an "outperform" rating and a $27.00 price target for the company. Lifesci Capital raised shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a report on Wednesday, June 18th. HC Wainwright initiated coverage on shares of Crescent Biopharma in a report on Monday. They issued a "buy" rating and a $25.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Crescent Biopharma in a report on Wednesday, June 25th. They issued a "buy" rating and a $28.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd.

Crescent Biopharma Price Performance

Crescent Biopharma stock traded up $0.02 during trading hours on Monday, hitting $13.95. The stock had a trading volume of 20,962 shares, compared to its average volume of 41,817. The company has a market cap of $272.72 million, a PE ratio of -0.40 and a beta of 1.51. Crescent Biopharma has a 12-month low of $10.83 and a 12-month high of $63.00. The stock has a 50-day simple moving average of $13.88.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE acquired a new stake in Crescent Biopharma in the 2nd quarter valued at $149,000. Jefferies Financial Group Inc. acquired a new position in Crescent Biopharma in the second quarter valued at approximately $437,000. Adage Capital Partners GP L.L.C. acquired a new position in Crescent Biopharma in the second quarter valued at approximately $1,629,000. Braidwell LP acquired a new position in Crescent Biopharma in the second quarter valued at approximately $4,221,000. Finally, Affinity Asset Advisors LLC acquired a new position in Crescent Biopharma in the second quarter valued at approximately $4,520,000. Hedge funds and other institutional investors own 75.19% of the company's stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.